Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 4/20 | 0.46 |
| ▸ | F7 | P08709 | 4/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.35 |
| ▸ | F3 | P13726 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | HPN | P05981 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15520640 | 0.86 | CHEK1 (0.38) | CHEK1F7FFAR1PPARGKDM4E | |
| SCHEMBL22134355 | 0.80 | CHEK1 (0.45) | CHEK1F7FFAR1PPARGKDM4E | |
| SCHEMBL15520638 | 0.79 | CHEK1 (0.41) | CHEK1F7FFAR1PPARGKDM4E | |
| SCHEMBL952431 | 0.75 | SCD (0.40) | CHEK1ALDH1A1MAPT | |
| SCHEMBL15520108 | 0.73 | TLR7 (0.36) | CHEK1FFAR1PPARGKDM4EALDH1A1 | |
| SCHEMBL15520639 | 0.73 | CHEK1 (0.38) | CHEK1F7FFAR1PPARGKDM4E | |
| SCHEMBL15520027 | 0.73 | MAPT (0.42) | CHEK1FFAR1KDM4EALDH1A1MAPT | |
| SCHEMBL950328 | 0.73 | SMN1; SMN2 (0.39) | CHEK1KDM4EMAPT | |
| SCHEMBL951161 | 0.72 | KLKB1 (0.41) | CHEK1MAPT | |
| SCHEMBL19493245 | 0.72 | SMN1; SMN2 (0.38) | CHEK1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604975-B2 | Indolyl-pyridone derivatives having checkpoint kinase 1 inhibitory activity | VERNALIS (R&D) LTD (GB) | 2017-03-28 | — | — | US | disclosed |
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | VERNALIS (R&D) LTD (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099736-A1 | Indolyl-Pyridone Derivatives Having Checkpoint Kinase 1 Inhibitory Activity | CHEK1, CHEK2, RAD1 | CHEK1 1/4885F7 2428/4885FFAR1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.